BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS:Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS:Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).
RCT Entities:
BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS: Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS:Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).
Authors: Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de Las Heras; Maria V Mateos; Maria C López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Joan Bladé; Juan J Lahuerta; Alberto Orfao; Jesús F San Miguel Journal: Blood Date: 2008-07-31 Impact factor: 22.113
Authors: Paul G Richardson; Robert L Schlossman; Edie Weller; Teru Hideshima; Constantine Mitsiades; Faith Davies; Richard LeBlanc; Laurence P Catley; Deborah Doss; Kathleen Kelly; Mary McKenney; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Rebecca Rich; Joan J Ryoo; Dharminder Chauhan; Kathe Balinski; Jerome Zeldis; Kenneth C Anderson Journal: Blood Date: 2002-11-01 Impact factor: 22.113
Authors: Bart Barlogie; Michel Attal; John Crowley; Frits van Rhee; Jackie Szymonifka; Philippe Moreau; Brian G M Durie; Jean-Luc Harousseau Journal: J Clin Oncol Date: 2010-01-19 Impact factor: 44.544
Authors: Henk M Lokhorst; Bronno van der Holt; Sonja Zweegman; Edo Vellenga; Sandra Croockewit; Marinus H van Oers; Peter von dem Borne; Pierre Wijermans; Ron Schaafsma; Okke de Weerdt; Shulamiet Wittebol; Michel Delforge; Henriëtte Berenschot; Gerard M Bos; Kon-Siong G Jie; Harm Sinnige; Marinus van Marwijk-Kooy; Peter Joosten; Monique C Minnema; Rianne van Ammerlaan; Pieter Sonneveld Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Andrew Spencer; H Miles Prince; Andrew W Roberts; Ian W Prosser; Kenneth F Bradstock; Luke Coyle; Devinder S Gill; Noemi Horvath; John Reynolds; Nola Kennedy Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Bart Barlogie; Mauricio Pineda-Roman; Frits van Rhee; Jeff Haessler; Elias Anaissie; Klaus Hollmig; Yazan Alsayed; Sarah Waheed; Nathan Petty; Joshua Epstein; John D Shaughnessy; Guido Tricot; Maurizio Zangari; Jerome Zeldis; Sol Barer; John Crowley Journal: Blood Date: 2008-05-20 Impact factor: 22.113
Authors: Nisha S Joseph; Jonathan L Kaufman; Madhav V Dhodapkar; Craig C Hofmeister; Dhwani K Almaula; Leonard T Heffner; Vikas A Gupta; Lawrence H Boise; Sagar Lonial; Ajay K Nooka Journal: J Clin Oncol Date: 2020-04-16 Impact factor: 44.544
Authors: Christian Straka; Peter Liebisch; Hans Salwender; Burkhard Hennemann; Bernd Metzner; Stefan Knop; Sigrid Adler-Reichel; Christian Gerecke; Hannes Wandt; Martin Bentz; Tim Hendrik Bruemmendorf; Marcus Hentrich; Michael Pfreundschuh; Hans-Heinrich Wolf; Orhan Sezer; Ralf Bargou; Wolfram Jung; Lorenz Trümper; Bernd Hertenstein; Else Heidemann; Helga Bernhard; Nicola Lang; Norbert Frickhofen; Holger Hebart; Ralf Schmidmaier; Andreas Sandermann; Tobias Dechow; Albrecht Reichle; Brigitte Schnabel; Kerstin Schäfer-Eckart; Christian Langer; Martin Gramatzki; Axel Hinke; Bertold Emmerich; Hermann Einsele Journal: Haematologica Date: 2016-08-04 Impact factor: 9.941
Authors: Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Yin Yan Xu; Michael Kalos; Ling Cai; Hong-Bin Fang; Brendan M Weiss; Ashraf Badros; Saul Yanovich; Gorgun Akpek; Patricia Tsao; Alan Cross; Dean Mann; Sunita Philip; Naseem Kerr; Andrea Brennan; Zhaohui Zheng; Kathleen Ruehle; Todd Milliron; Scott E Strome; Andres M Salazar; Bruce L Levine; Carl H June Journal: Clin Cancer Res Date: 2014-02-11 Impact factor: 12.531
Authors: E Terpos; D Christoulas; E Kastritis; M Roussou; M Migkou; E Eleutherakis-Papaiakovou; M Gavriatopoulou; M Gkotzamanidou; N Kanellias; E Manios; C Papadimitriou; M A Dimopoulos Journal: Leukemia Date: 2013-09-18 Impact factor: 11.528